... pathway inhibitor, and activated protein C [8-10] Although several of these agents have been evaluated in large clinical trials, only recombinant human activated protein C (drotrecogin alfa (activated) ... recent completion of several clinical studies evaluating DrotAA as an adjunctive treatment in severe sepsis affords an opportunity to improve our understanding of patients presenting with clinical ... this analysis DrotAA, drotrecogin alfa (activated); ICH, intracranial hemorrhage; MD, meningococcal disease; MEN, meningitis; PF, purpura fulminans; SBE, serious bleeding event During DrotAA infusion,...